Efficacy of tyrosine kinase inhibitors in the treatment of brain metastases from Her-2 positive breast cancer:a single-arm meta-analysis
Objective To investigate the efficacy of tyrosine kinase inhibitors(TKIs)in Her-2 positive breast cancer brain metastasis(BCBM).Methods The clinical studies of TKIs in the treatment of Her-2 positive BCBM from the establishment of the database to April 11th,2022(PubMed,Cochrane Library,Embase)were searched,and the meta-analysis was conducted with STATA17.0.Results A total of 50 studies were included,of which 3 were about TKIs monotherapy and 12 were about combination therapy.Meta-analysis showed that the efficacy of TKIs monotherapy was poor,and there was no significant difference in overall survival(OS)between it and the treatment without TKIs(P>0.05).However,the efficacy of TKIs combination therapy was improved:the OS of TKIs combination therapy was better than that of the treatment without TKIs,treatment without anti-Her-2 drugs or trastuzumab monotherapy.The progression of central nervous system(CNS)was the main progression mode of TKIs monotherapy or combined drug therapy,with an incidence of about 59.0%-82.2%,while the CNS recurrence rate of TKIs combined with radiotherapy was reduced to 22.9%.Conclusion TKIs-based combination therapy can improve the prognosis of Her-2 positive BCBM,but the CNS recurrence rate is still high.TKIs combined with radiotherapy can reduce the CNS recurrence rate,but there are few related prospective clinical studies,and more prospective clinical studies are needed to further determine the best treatment strategy.
Her-2 positive breast cancerBrain metastasisTKIsmeta analysis
万方数据
维普
